Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 1 of 13, showing 5 Applications out of 61 total, starting on record 1, ending on 5

# Protocol No Study Title Investigator(s) & Site(s) Application Status

1.

ECCT/11/01/02   EARNEST
    EARNEST : Europe -Africa Research Network for Evaluation of Second-line Therapy           
Principal Investigator(s)
1. Abraham Mosigisi Siika
Site(s) in Kenya
Moi University Clinical Research Centre
 
Trial Status Completed
Protocol Date 06-09-2010
View

2.

ECCT/11/07/02   REMEMBER
    A5274/REMEMBER "Reducing Early Mortality and Early Morbidity by Empiric Tuberculosis Treatment Regimens"   
Principal Investigator(s)
1. Abraham Mosigisi Siika
Site(s) in Kenya
1. Moi University Clinical Research Centre (Uasin Gishu county)
2. Walter Reed Project (Kericho county)
 
Trial Status Writing-up
Protocol Date 29-10-2010
View

3.

ECCT/11/08/04   SSG/PM Pharmacovigilance Plan
    Pharmacovigilance Plan to Monitor the Safety and Effectiveness of Combination of Sodium Stibogluconate and Paramomycin in the Treatment of Visceral Leishmaniasis   The SSG/PM (Sodium Stibogluconate/Paromycin) Pharmacovigilance Plan aims to collect pharmacovigilance information during the early post-approval period of SSG/PM as soon as SSG/PM is in use by the Ministries of Health for treatment of Visceral Leishmaniasis.   During the early post-approval period, SSG/PM might be used in settings different from clinical trials and a much larger and diverse population might be exposed in a relatively short timeframe. The pharmacovigilance (PV) programme is crucial in order to continuously evaluate the risk-benefit ratio in different groups of patients and in different contexts   The Pharmacovigilance study in Kenya involves the key sentinel site of Kacheliba kala-azar treatment centre, (where MSF-OCG is based). A similar protocol is ongoing in Sudan and planned for Uganda. The Pharmacovigilance plan primary objectives are: a) to continuously monitor the safety profile of SSG/PM during the first 2 years that follow its authorization for use in East Africa; b) to identify additional risks that have not been reported in pre-approval clinical studies; c) to determine whether SSG/PM adverse reactions are of higher concern in specific groups of patients; d) to monitor the treatment failure rate of SSG/PM and e) to monitor any evidence in site variation in terms of SSG/PM effectiveness and safety.   The target population are all VL patients treated with SSG/PM in Kenya and other participating countries. A registry is used independently from clinical presentation and demographic characteristics. Diagnostic, treatment and discharge procedures are consistent with the routine clinical practice in use in the health facility. A standard form is used to collect information. No blood/tissue samples or extra medical procedures are required for the PV plan.   Every 3 months, descriptive statistics are produced. In particular, the total number of SAE, the number of treatment-related SAE and the number of treatment failures are calculated. The Steering Committee is responsible for data review.   In Kenya Ethical and Regulatory approval is sought through KEMRI ERC and Pharmacy and Poisons Board. Informed consent document is distributed to each patient treated with SSG/PM. The aim of the PV plan is discussed, as well as the measures taken to ensure confidentiality of the data collected.   
Principal Investigator(s)
1. Monique Wasunna
Site(s) in Kenya
1. Kacheliba Kala-azar treatment centre (West Pokot county)
2. Kimalel Health Centre (Baringo county)
 
Trial Status Completed
Protocol Date 24-05-2012
View

4.

ECCT/11/09/01   Randomized Comparison of ART Alone versus ART with Immediate Chemotherapy
    A Randomized Evaluation of Antiretroviral Therapy Alone or with Delayed Chemotherapy versus Antiretroviral Therapy with Immediate Adjunctive Chemotherapy for Treatment of Limited Stage AIDS-KS in Resource-Limited Settings (REACT-KS)   
Principal Investigator(s)
1. Deborah C. Langat
Site(s) in Kenya
KEMRI/Walter Reed Project
 
Trial Status Writing-up
Protocol Date 11-11-2011
View

5.

ECCT/12/04/01  
    A double-masked randomised placebo-controlled trial of adjuvant topical 5-fluorouracil (5FU) treatment following surgical excision of ocular surface squamous neoplasia.       
Principal Investigator(s)
1. Stephen Gichuhi
Site(s) in Kenya
1. Kenyatta National Hospital (Nairobi City county)
2. PCEA Kikuyu Eye Unit (Kiambu county)
3. Sabatia Eye Hospital (Kakamega county)
4. Kitale District Hospital, Eye Unit (Trans Nzoia county)
5. Homa Bay District Hospital, Eye Unit (Homa Bay county)
 
Trial Status In follow-up
Protocol Date 05-04-2012
View